Pre-clinical and clinical endpoint assays for cystic fibrosis gene therapy  Uta Griesenbach, A. Christopher Boyd  Journal of Cystic Fibrosis  Volume 4, Issue 2, Pages 89-100 (May 2005) DOI: 10.1016/j.jcf.2005.02.002 Copyright © 2005 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 Efficient transfection of mouse nasal epithelium with recombinant Sendai virus expressing β-galactosidase. Close to 100% of airway epithelial cells express β-galactosidase, here visible as blue precipitate. Journal of Cystic Fibrosis 2005 4, 89-100DOI: (10.1016/j.jcf.2005.02.002) Copyright © 2005 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Detection of endogenous CFTR in human airway epithelial cells using an anti-CFTR specific antibody. Apically localised CFTR protein is visible as a green layer and the DAPI-stained cell nucleus appears in blue. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Journal of Cystic Fibrosis 2005 4, 89-100DOI: (10.1016/j.jcf.2005.02.002) Copyright © 2005 European Cystic Fibrosis Society Terms and Conditions

Fig. 3 Nasal potential difference measurements in CF and non-CF murine nasal epithelium. Following measurement of basal PD (BL), a solution containing amiloride (Am) is perfused into the nasal cavity, which leads to a drop of PD in CF and non-CF mice. Subsequently the nasal epithelium is perfused with a low chloride solution (LC), which generates a driving force for chloride secretion and increased PD in non-CF, but not in CF mice. Journal of Cystic Fibrosis 2005 4, 89-100DOI: (10.1016/j.jcf.2005.02.002) Copyright © 2005 European Cystic Fibrosis Society Terms and Conditions